Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal year ended September 30, 2023, on Monday November 27, 2023.
- NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal year ended September 30, 2023, on Monday November 27, 2023.
- Management will host a conference call on Monday November 27, 2023, at 8:30 am ET to review financial results and provide an update on the execution of the Company’s growth strategy.
- Following management’s remarks, there will be a question-and-answer session.
- A replay of the conference call will also be available on Anavex’s website for up to 30 days.